Hantz Financial Services’s Viking Therapeutics VKTX Stock Holding History

Hantz Financial Services’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$0	Sell	1 -25	-96%	-$808	﹤0.01%	2649
2026 Q1	$1K	Buy	26 +25	+2,500%	+$804	﹤0.01%	2406
2025 Q4	$0	Hold	1	–	–	﹤0.01%	2546
2025 Q3	$0	Hold	1	–	–	﹤0.01%	2458
2025 Q2	$0	Sell	1 -68	-99%	-$1.79K	﹤0.01%	2309
2025 Q1	$2K	Buy	+69	New	+$2.18K	﹤0.01%	1436
2023 Q4	–	Sell	-40	Closed	–	–	1230
2023 Q3	$0	Hold	40	–	–	﹤0.01%	1190
2023 Q2	$1K	Hold	40	–	–	﹤0.01%	1061
2023 Q1	$1K	Buy	+40	New	+$413	﹤0.01%	1082

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Hantz Financial Services's VKTX Position: Q2 2026 in Review

Hantz Financial Services reduced its Viking Therapeutics (VKTX) stake by 96% in Q2 2026, selling an estimated $808 and leaving 1 share worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2649.

Hantz Financial Services first reported a position in VKTX in Q1 2023 and has held it in 9 quarters since. The position peaked at $2K in Q1 2025. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

Hantz Financial Services held 1 share of Viking Therapeutics worth $0 as of Q2 2026.
Hantz Financial Services sold 25 Viking Therapeutics shares in Q2 2026, an estimated $808.
Viking Therapeutics made up ﹤0.01% of Hantz Financial Services's portfolio in Q2 2026, its #2649 holding.
Hantz Financial Services first reported a position in Viking Therapeutics in Q1 2023 and has held it in 9 quarters since.
Hantz Financial Services's Viking Therapeutics position peaked at $2K in Q1 2025.
436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.